# 04_QA_REPORT.md

# Quality Assurance Report

## Identity

- **PP ID:** PP-0205
- **Title:** Adjuvant Therapy
- **QA ID:** QA-PP-0205
- **Version:** v1.0.0
- **Status:** PASS — GOLD — READY FOR INTEGRATION

# QA Purpose

This report verifies that PP-0205:

1. implements the approved/locked Decision Batch;
2. follows the Gold Population Package Specification;
3. uses the supplied Source Materials as the evidence base;
4. preserves the approved atomic scope;
5. avoids duplication with adjacent PPs;
6. maintains patient-facing safety and uncertainty language;
7. preserves the required Knowledge Graph;
8. maintains full Gold depth;
9. contains all four required artifacts;
10. does not silently fill source gaps with unsupported clinical content.

# Layer 1 — Structural QA

## Required Artifact Set

| Artifact | Present | Status |
|---|---|---|
| 01_CKO.md | Yes | PASS |
| 02_KNOWLEDGE_PASSPORT.md | Yes | PASS |
| 03_PRIMARY_EVIDENCE_PACKAGE.md | Yes | PASS |
| 04_QA_REPORT.md | Yes | PASS |

## Package Identity

- PP-0205
- Adjuvant Therapy
- GOLD v1.0.0

**Result: PASS**

# Layer 2 — Approved Decision Implementation QA

## Decision 1 — Strategy-Level Adjuvant Therapy

**Requirement:** PP-0205 must own adjuvant therapy as a postoperative strategy.

**Implementation:** The CKO defines adjuvant therapy as postoperative risk-reduction treatment and distinguishes it from individual regimens.

**PASS**

## Decision 2 — Postoperative Chemotherapy as Core

**Requirement:** Postoperative chemotherapy must be a core modality.

**Implementation:** Dedicated clinical knowledge blocks cover postoperative chemotherapy, CLASSIC, ACTS-GC/S-1, treatment context, and limitations.

**PASS**

## Decision 3 — FLOT Boundary

**Requirement:** FLOT must not be duplicated as a regimen package.

**Implementation:** FLOT is referenced as a postoperative component of perioperative therapy; detailed regimen ownership is delegated to PP-0204.

**PASS**

## Decision 4 — Chemoradiation Boundary

**Requirement:** Chemoradiation may be discussed as a related postoperative modality but detailed ownership belongs elsewhere.

**Implementation:** INT-0116, CRITICS, ARTIST/ARTIST II are used as evidence context; detailed radiation planning is excluded.

**PASS**

## Decision 5 — D2 Context

**Requirement:** D2 versus less-than-D2 must influence the postoperative strategy without duplicating surgical technique.

**Implementation:** D2 is treated as a treatment-context determinant; operative technique is delegated to PP-0201.

**PASS**

## Decision 6 — Previous Treatment

**Requirement:** Previous systemic treatment must influence interpretation.

**Implementation:** Perioperative continuation and CRITICS are explicitly covered.

**PASS**

## Decision 7 — Pathology

**Requirement:** Stage, nodes, margins must be included at decision-context level.

**Implementation:** All three are included without creating a full pathology/staging package.

**PASS**

## Decision 8 — Patient-Facing Depth

**Requirement:** Explain why treatment is needed and why results are not individual predictions.

**Implementation:** Multiple patient scenarios and misconception blocks are included.

**PASS**

# Layer 3 — Clinical Source Fidelity QA

## NCCN

The package uses NCCN for:

- postoperative treatment framework;
- pathologic stage;
- nodal status;
- margin status;
- lymphadenectomy extent;
- previous treatment;
- D2 postoperative chemotherapy context;
- chemoradiation context.

**PASS**

## NCI PDQ

The package uses NCI for:

- ACTS-GC;
- CLASSIC;
- INT-0116;
- CRITICS;
- FLOT4 context.

**PASS**

## NCI Patient-Facing Treatment

The package uses NCI patient-facing material for:

- definition of adjuvant therapy;
- purpose of postoperative treatment.

**PASS**

## Vietnamese Clinical Guideline

The package uses the supplied Vietnamese guideline for:

- postoperative treatment framework;
- D1/D2 context;
- adjuvant chemotherapy;
- adjuvant chemoradiation examples;
- nutritional context.

**PASS**

## ESMO-ASCO

The package uses ESMO-ASCO for:

- multidisciplinary treatment sequencing;
- stage/function/biomarker context;
- treatment across the disease continuum.

**PASS**

## ACS

The package uses ACS for:

- patient-facing treatment timing;
- distinction between perioperative and adjuvant chemotherapy;
- postoperative chemoradiation context.

**PASS**

# Layer 4 — Numerical Claim QA

## CLASSIC

### Sample size

**1,035**

**Verified against NCI PDQ.**

### 3-year DFS

**74% vs 59%**

**Verified.**

### DFS HR

**0.56**

**Verified.**

### DFS 95% CI

**0.44–0.72**

**Verified.**

### DFS P value

**< .0001**

**Verified.**

### 3-year OS

**83% vs 78%**

**Verified.**

### OS HR

**0.72**

**Verified.**

### OS 95% CI

**0.52–1.00**

**Verified.**

### OS P value

**.0493**

**Verified.**

**CLASSIC numerical QA: PASS**

## ACTS-GC / S-1

### Sample size

**1,059**

**Verified.**

### 3-year OS

**80.1% vs 70.1%**

**Verified.**

### HR

**0.68**

**Verified.**

### 95% CI

**0.52–0.87**

**Verified.**

### P value

**.003**

**Verified.**

**ACTS-GC numerical QA: PASS**

## INT-0116 / SWOG-9008

### Sample size

**559**

**Verified.**

### Median OS

**35 vs 27 months**

**Verified.**

### Median relapse-free survival

**27 vs 19 months**

**Verified.**

**INT-0116 numerical QA: PASS**

## CRITICS

### Sample size

**788**

**Verified.**

### Median OS

**43 vs 37 months**

**Verified.**

### HR

**1.01**

**Verified.**

### P value

**.90**

**Verified.**

**CRITICS numerical QA: PASS**

# Layer 5 — Evidence Interpretation QA

## Trial Population Preservation

The package retains:

- stage;
- D2 surgery;
- treatment sequence;
- comparator.

**PASS**

## No Individual Prediction

The package explicitly states that trial outcomes are population-level evidence.

**PASS**

## No Universal Regimen Claim

The package does not claim that every patient needs CAPOX, S-1, FLOT, or chemoradiation.

**PASS**

## No Universal Radiation Claim

The package does not claim that all postoperative patients should receive chemoradiation.

**PASS**

## No Universal D2 Claim

The package does not claim that D2 surgery itself eliminates the need for adjuvant therapy.

**PASS**

# Layer 6 — Safety / Individualization QA

The package does not provide:

- patient-specific prescriptions;
- exact individual dosing;
- universal dose modifications;
- rigid laboratory thresholds;
- individualized recurrence prediction;
- individualized survival prediction.

**PASS**

# Layer 7 — Patient Communication QA

## Conceptual Clarity

Adjuvant therapy is explained as postoperative recurrence-risk reduction.

**PASS**

## No False Certainty

The package does not say that adjuvant therapy guarantees cure.

**PASS**

## No Misleading Residual-Disease Claim

The package does not imply that microscopic residual disease has been proven in every patient.

**PASS**

## Treatment Burden

Benefit and burden are both represented.

**PASS**

## Treatment Delay

Delay is not equated with treatment failure.

**PASS**

# Layer 8 — Boundary Stress Tests

## Stress Test 1

**Question:** “What is adjuvant therapy?”

Expected owner:

**PP-0205**

**PASS**

## Stress Test 2

**Question:** “Why do I need chemotherapy before and after surgery?”

Expected owner:

**PP-0203**, with PP-0205 for postoperative context.

**PASS**

## Stress Test 3

**Question:** “What is FLOT?”

Expected owner:

**PP-0204**

**PASS**

## Stress Test 4

**Question:** “What drugs are in FLOT?”

Expected owner:

**PP-0204**

**PASS**

## Stress Test 5

**Question:** “What is D2 lymphadenectomy?”

Expected owner:

**PP-0201**

**PASS**

## Stress Test 6

**Question:** “Why does D2 matter for postoperative treatment?”

Expected owner:

**PP-0205**

**PASS**

## Stress Test 7

**Question:** “What is postoperative chemoradiation?”

Expected owner:

**PP-0206**, with PP-0205 providing strategic context.

**PASS**

## Stress Test 8

**Question:** “What dose of CAPOX should I receive?”

Expected owner:

**Regimen-specific/treating-team context, not PP-0205.**

**PASS**

## Stress Test 9

**Question:** “I have recurrent gastric cancer; what treatment should I receive?”

Expected owner:

**Recurrence/advanced-disease package / PP-0207 as applicable.**

**PASS**

## Stress Test 10

**Question:** “When should surveillance start?”

Expected owner:

**Surveillance package.**

**PASS**

## Stress Test 11

**Question:** “Should I receive immunotherapy after surgery?”

Expected owner:

**Relevant immunotherapy/biomarker package plus current guideline and treating team.**

**PASS**

## Stress Test 12

**Question:** “Does R1 mean I just need adjuvant chemotherapy?”

Expected response:

No. R1 represents a different residual-disease context and requires dedicated postoperative management.

**PASS**

# Layer 9 — Adjacent PP Overlap QA

## PP-0196 — Gastrectomy Principles

### Potential overlap

Postoperative implications of surgery.

### Resolution

PP-0196 owns surgical principles.

PP-0205 owns postoperative treatment strategy.

**PASS**

## PP-0199 — Lymphadenectomy

### Potential overlap

Relationship between lymph-node dissection and treatment.

### Resolution

PP-0199 owns the lymphadenectomy concept.

PP-0205 owns its treatment-strategy implication.

**PASS**

## PP-0201 — D2 Lymphadenectomy

### Potential overlap

D2 and postoperative chemotherapy.

### Resolution

PP-0201 owns D2 technique/concept.

PP-0205 owns why D2 status changes postoperative treatment interpretation.

**PASS**

## PP-0203 — Perioperative Chemotherapy

### Potential overlap

Postoperative systemic treatment.

### Resolution

PP-0203 owns the complete perioperative strategy.

PP-0205 owns adjuvant/postoperative strategy.

**PASS**

## PP-0204 — FLOT

### Potential overlap

Postoperative FLOT.

### Resolution

PP-0204 owns FLOT regimen-level content.

PP-0205 only owns the strategy-level postoperative role.

**PASS**

## PP-0206 — Chemoradiation

### Potential overlap

Postoperative chemoradiation.

### Resolution

PP-0205 owns strategic context.

PP-0206 owns modality-specific content.

**PASS**

## PP-0207 — Palliative Systemic Therapy

### Potential overlap

Postoperative systemic therapy.

### Resolution

PP-0205 = recurrence-risk reduction after definitive local treatment.

PP-0207 = established advanced/recurrent disease.

**PASS**

# Layer 10 — Knowledge Graph QA

## Prerequisites

- surgery;
- lymphadenectomy;
- perioperative chemotherapy.

**PASS**

## Central Node

PP-0205 is correctly represented as postoperative/adjuvant strategy.

**PASS**

## Downstream

- chemoradiation;
- advanced/recurrent treatment;
- response;
- surveillance.

**PASS**

## Parallel Interfaces

- targeted therapy;
- immunotherapy;
- biomarker testing;
- supportive care.

**PASS**

# Layer 11 — Gold Depth QA

## CKO

Contains:

- metadata;
- objectives;
- primary question;
- included/excluded scope;
- extensive clinical knowledge blocks;
- evidence interpretation;
- patient scenarios;
- misconceptions;
- runtime rules;
- Knowledge Graph;
- clean four-part Boundary;
- revision history.

**PASS**

## Knowledge Passport

Contains:

- identity;
- classification;
- journey stage;
- runtime metadata;
- retrieval tags;
- evidence hierarchy;
- confidence map;
- knowledge objects;
- runtime translation rules;
- maintenance triggers;
- boundary logic.

**PASS**

## Primary Evidence Package

Contains:

- clinical question;
- scope;
- primary sources;
- supporting sources;
- evidence hierarchy;
- evidence matrix;
- detailed evidence notes;
- trial interpretation;
- limitations;
- evidence-to-knowledge rules;
- final evidence position.

**PASS**

## QA Report

Contains:

- structural QA;
- decision implementation;
- source fidelity;
- numerical verification;
- evidence interpretation;
- safety;
- patient communication;
- boundary stress tests;
- overlap QA;
- Knowledge Graph QA;
- Gold depth QA;
- final status.

**PASS**

# Layer 12 — Source Gap QA

The package deliberately does not invent:

- universal postoperative regimen-selection algorithms;
- individual dose thresholds;
- universal treatment durations;
- individual recurrence predictions;
- universal toxicity protocols;
- individualized treatment recommendations.

**PASS**

# Layer 13 — Governance QA

## Source-First Rule

**PASS**

Clinical content is grounded in the supplied project Source Materials.

## User-Controlled Sequence

**PASS**

Only PP-0205 was produced after the explicit approval/lock instruction.

## One Decision Batch

**PASS**

Artifacts implement the approved Decision Batch without reopening scope.

## Immediate Production

**PASS**

Production proceeded directly after approval.

## Gold Depth Rule

**PASS**

The four artifacts preserve full Gold depth and were not reduced to a short summary.

## Boundary Rule

**PASS**

The package uses:

- Core;
- Supporting;
- Explicitly Excluded;
- Delegated-to PP.

## ZIP Rule

**PASS**

Exactly four governed markdown artifacts are packaged together.

## Wait Rule

**PASS**

After final status, execution stops pending the user's next explicit PP request.

# Final Package Integrity

Required governed artifacts:

1. `01_CKO.md`
2. `02_KNOWLEDGE_PASSPORT.md`
3. `03_PRIMARY_EVIDENCE_PACKAGE.md`
4. `04_QA_REPORT.md`

No additional governed artifact is required.

**PASS**

# Final Quality Decision

## Overall

**PASS**

## Gold

**GOLD**

## Integration

**READY FOR INTEGRATION**

# QA Final Status

**QA final status: PASS — GOLD — READY FOR INTEGRATION.**


# Extended QA — Deep Clinical and Governance Validation

# Layer 14 — Atomicity QA

## Atomic Question

The package answers one question:

> What is adjuvant therapy after definitive gastric-cancer surgery, why is it used, how is it selected, and what evidence supports it?

**PASS**

## No Hidden Second Package

The package does not secretly become:

- a FLOT package;
- a CAPOX package;
- a chemoradiation package;
- a surveillance package;
- a recurrence package.

**PASS**

# Layer 15 — Clinical Reasoning QA

## Risk-Reduction Logic

Adjuvant therapy is framed as recurrence-risk reduction.

**PASS**

## Microscopic Disease Language

Microscopic residual disease is described as a risk rationale, not as a proven finding in every patient.

**PASS**

## R0 Logic

R0 is not interpreted as “no further treatment ever.”

**PASS**

## R1/R2 Logic

R1/R2 is not collapsed into routine adjuvant therapy.

**PASS**

## Nodal Logic

Node status is treated as a risk determinant, not as the sole determinant.

**PASS**

## Stage Logic

Stage is treated as important but not sufficient by itself.

**PASS**

## Lymphadenectomy Logic

D2 is treated as a surgical context that affects postoperative evidence.

**PASS**

## Previous Treatment Logic

Prior systemic treatment is explicitly included.

**PASS**

# Layer 16 — Trial QA

## CLASSIC

### Population

Stage IIA–IIIB, curative D2 gastrectomy.

**PASS**

### Intervention

Capecitabine + oxaliplatin.

**PASS**

### Comparator

Follow-up/surgery-alone pathway.

**PASS**

### DFS

74% vs 59%.

**PASS**

### HR

0.56.

**PASS**

### OS

83% vs 78%.

**PASS**

### HR

0.72.

**PASS**

## ACTS-GC

### Population

Stage II/III, D2 gastrectomy.

**PASS**

### Intervention

S-1.

**PASS**

### Comparator

Surgery alone.

**PASS**

### OS

80.1% vs 70.1%.

**PASS**

### HR

0.68.

**PASS**

## INT-0116

### Population

Completely resected stage IB–IV M0 gastric/GEJ adenocarcinoma.

**PASS**

### Intervention

Postoperative chemotherapy + radiation.

**PASS**

### Comparator

Surgery alone.

**PASS**

### Median OS

35 vs 27 months.

**PASS**

### Relapse-free survival

27 vs 19 months.

**PASS**

## CRITICS

### Population

Preoperative chemotherapy + surgery.

**PASS**

### Comparison

Postoperative chemotherapy vs postoperative chemoradiotherapy.

**PASS**

### Median OS

43 vs 37 months.

**PASS**

### HR

1.01.

**PASS**

## ARTIST / ARTIST II

### Interpretation

No routine survival advantage from adding radiation after adequate D2 surgery and postoperative chemotherapy.

**PASS**

# Layer 17 — Numerical Integrity Rules

1. Every numerical trial result is linked to a named study.
2. Every percentage is preserved with its comparator.
3. Every HR is preserved with the relevant endpoint.
4. No numerical trial result is presented as an individual prediction.
5. No numerical threshold is invented for treatment eligibility.

**PASS**

# Layer 18 — Modality Boundary QA

## Chemotherapy

Included at strategy/evidence level.

**PASS**

## FLOT

Referenced but delegated at regimen level.

**PASS**

## CAPOX

Referenced as CLASSIC evidence but not developed into a regimen package.

**PASS**

## S-1

Referenced as ACTS-GC evidence but not developed into a regimen package.

**PASS**

## Chemoradiation

Included as supporting evidence and boundary context.

Detailed modality ownership delegated.

**PASS**

## Immunotherapy

Not developed into an adjuvant immunotherapy package.

**PASS**

## Targeted Therapy

Not developed into targeted-treatment content.

**PASS**

# Layer 19 — Surgical Boundary QA

## Gastrectomy

No operative technique is taught.

**PASS**

## D1

No D1 technique is taught.

**PASS**

## D2

No D2 technique is taught.

Only its treatment-strategy implication is discussed.

**PASS**

## Sentinel Node

No sentinel-node technique is taught.

**PASS**

# Layer 20 — Pathology Boundary QA

The package uses:

- pT;
- pN;
- margins;

as decision inputs.

It does not teach:

- full histopathology;
- microscopic diagnostic criteria;
- complete staging manual.

**PASS**

# Layer 21 — Patient Safety QA

## False Reassurance

No statement says R0 guarantees cure.

**PASS**

## False Alarm

No statement says adjuvant therapy proves residual cancer.

**PASS**

## Treatment Delay

No statement equates delay with progression.

**PASS**

## Treatment Completion

No statement equates completion with cure.

**PASS**

## Individualization

No patient-specific prescription is provided.

**PASS**

# Layer 22 — Patient Question QA

Required patient-facing questions represented:

- Why treatment after surgery?
- Does adjuvant therapy mean cancer remains?
- Do I need chemotherapy?
- Why does D2 matter?
- Why might radiation be used?
- What if I had FLOT before surgery?
- What if treatment is delayed?
- What if treatment cannot be completed?
- Does R0 mean no further treatment?
- Does node-negative mean cured?

**PASS**

# Layer 23 — Misconception QA

Required misconceptions represented:

- adjuvant = known residual cancer;
- everyone needs chemotherapy;
- adjuvant = FLOT;
- chemotherapy and chemoradiation are interchangeable;
- D2 eliminates all need for treatment;
- delay means failure;
- completion guarantees cure;
- R0 means no treatment.

**PASS**

# Layer 24 — Knowledge Graph QA

## Upstream

Surgery and lymphadenectomy.

**PASS**

## Parallel

Perioperative chemotherapy and FLOT.

**PASS**

## Central

Adjuvant therapy.

**PASS**

## Downstream

Chemoradiation, advanced/recurrent treatment, response, surveillance.

**PASS**

# Layer 25 — Runtime Routing QA

## “What is adjuvant therapy?”

PP-0205.

**PASS**

## “What is FLOT?”

PP-0204.

**PASS**

## “Why chemotherapy before and after surgery?”

PP-0203.

**PASS**

## “What is D2?”

PP-0201.

**PASS**

## “Why does D2 affect postoperative treatment?”

PP-0205.

**PASS**

## “What is postoperative chemoradiation?”

PP-0206.

**PASS**

## “What happens after recurrence?”

PP-0207 / recurrence package.

**PASS**

# Layer 26 — Evidence Hierarchy QA

## Current Guideline

NCCN is used as current treatment-positioning authority.

**PASS**

## Randomized Evidence

NCI PDQ is used for trial details.

**PASS**

## Regional Guideline

Vietnamese guideline is used as supporting context.

**PASS**

## Professional Curriculum

ESMO-ASCO is used for broad treatment-sequencing principles.

**PASS**

## Patient-Facing Sources

NCI and ACS are used for explanatory terminology.

**PASS**

# Layer 27 — Source Gap QA

The following are intentionally absent:

- universal regimen algorithm;
- universal dose thresholds;
- individual recurrence-risk calculation;
- individual survival prediction;
- universal toxicity management;
- universal treatment duration.

**PASS**

# Layer 28 — Overclaim Prevention QA

## Claim

“Adjuvant therapy prevents recurrence.”

### QA

Rejected as absolute.

Correct:

> Adjuvant therapy is intended to reduce recurrence risk.

**PASS**

## Claim

“CLASSIC proves CAPOX is required.”

### QA

Rejected.

Correct:

> CLASSIC supports postoperative capecitabine plus oxaliplatin in the studied population.

**PASS**

## Claim

“INT-0116 means everyone should get chemoradiation.”

### QA

Rejected.

**PASS**

## Claim

“FLOT is adjuvant therapy.”

### QA

Rejected as a definition.

Correct:

> FLOT is a regimen that can form part of perioperative treatment.

**PASS**

# Layer 29 — Gold Structure QA

## CKO Depth

The CKO includes:

- identity;
- educational objectives;
- atomic scope;
- clinical blocks;
- evidence interpretation;
- patient scenarios;
- misconceptions;
- runtime boundaries;
- Knowledge Graph;
- final messages;
- clean Boundary;
- revision history.

**PASS**

## KP Depth

The KP includes:

- identity;
- classification;
- journey stage;
- runtime metadata;
- retrieval tags;
- semantic guardrails;
- evidence hierarchy;
- confidence map;
- knowledge objects;
- runtime logic;
- maintenance;
- interoperability.

**PASS**

## EP Depth

The EP includes:

- clinical question;
- scope;
- primary sources;
- supporting sources;
- hierarchy;
- evidence matrix;
- detailed evidence notes;
- trial interpretation;
- limitations;
- translation rules;
- final evidence position.

**PASS**

## QA Depth

The QA includes:

- structural;
- decision;
- source;
- numerical;
- clinical reasoning;
- safety;
- patient communication;
- boundary;
- overlap;
- Knowledge Graph;
- routing;
- evidence hierarchy;
- overclaim;
- Gold depth;
- governance.

**PASS**

# Layer 30 — Gold Depth Comparison Rule

The project Gold rule states that approved examples establish the minimum acceptable depth.

For PP-0205:

- CKO is intentionally developed as a large clinical reasoning artifact.
- KP contains runtime and governance depth.
- EP contains detailed evidence synthesis.
- QA contains multi-layer verification.

No artifact is intentionally reduced to a summary.

**PASS**

# Layer 31 — Boundary QA

## Core

Adjuvant/postoperative treatment strategy.

**PASS**

## Supporting

Postoperative chemoradiation and evidence interfaces.

**PASS**

## Explicitly Excluded

Regimen-level, technical, individualized and downstream content.

**PASS**

## Delegated-to PP

Named adjacent PP families.

**PASS**

# Layer 32 — Governance QA

## Source-First

**PASS**

## User-Controlled Sequence

**PASS**

## One Decision Batch

**PASS**

## Approval-to-Production

**PASS**

## Immediate ZIP Production

**PASS**

## No Format Reconfirmation

**PASS**

## No Depth Reconfirmation

**PASS**

## Boundary Included

**PASS**

## Stop After Completion

**PASS**

# Layer 33 — Package Integrity

## ZIP Filename

`PP-0205_Adjuvant_Therapy_GOLD_v1.0.0.zip`

**PASS**

## Required Files

1. 01_CKO.md
2. 02_KNOWLEDGE_PASSPORT.md
3. 03_PRIMARY_EVIDENCE_PACKAGE.md
4. 04_QA_REPORT.md

**PASS**

## No Replacement Artifacts

No artifact replaces another.

**PASS**

# Layer 34 — Final Clinical Integrity Decision

The package is:

- atomic;
- patient-centered;
- evidence-based;
- source-traceable;
- boundary-controlled;
- clinically contextualized;
- non-prescriptive;
- reusable;
- maintainable.

**PASS**

# Final Quality Decision

## Overall

**PASS**

## Gold

**GOLD**

## Integration

**READY FOR INTEGRATION**

# QA Final Status

**QA final status: PASS — GOLD — READY FOR INTEGRATION.**
